Certara, Inc. (NASDAQ:CERT - Get Free Report) SVP Richard M. Traynor sold 3,000 shares of the company's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $18.00, for a total transaction of $54,000.00. Following the completion of the transaction, the senior vice president now owns 173,524 shares in the company, valued at approximately $3,123,432. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Certara Stock Down 0.4 %
CERT opened at $16.88 on Thursday. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.28. The firm has a 50 day moving average price of $17.57 and a 200-day moving average price of $15.89. Certara, Inc. has a twelve month low of $11.81 and a twelve month high of $24.96. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -48.23, a PEG ratio of 1.84 and a beta of 1.63.
Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.04). Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. The business had revenue of $88.01 million for the quarter, compared to analysts' expectations of $86.80 million. Equities research analysts forecast that Certara, Inc. will post 0.29 earnings per share for the current year.
Analyst Upgrades and Downgrades
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
Several brokerages have recently issued reports on CERT. Jefferies Financial Group upped their target price on shares of Certara from $14.00 to $15.50 and gave the stock a "hold" rating in a research note on Friday, March 1st. Leerink Partnrs reiterated a "market perform" rating on shares of Certara in a research note on Monday, February 26th. Barclays upped their target price on shares of Certara from $16.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Thursday, January 25th. SVB Leerink initiated coverage on shares of Certara in a research note on Monday, February 26th. They issued a "market perform" rating and a $19.00 target price on the stock. Finally, UBS Group boosted their price objective on shares of Certara from $17.00 to $20.00 and gave the company a "neutral" rating in a report on Friday, March 1st. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $19.64.
Get Our Latest Stock Analysis on CERT
Institutional Trading of Certara
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CERT. Tower Research Capital LLC TRC increased its holdings in Certara by 584.8% during the second quarter. Tower Research Capital LLC TRC now owns 1,356 shares of the company's stock valued at $25,000 after buying an additional 1,158 shares during the last quarter. Pineridge Advisors LLC purchased a new stake in shares of Certara in the fourth quarter worth $28,000. State of Wyoming increased its stake in shares of Certara by 103.1% in the second quarter. State of Wyoming now owns 2,027 shares of the company's stock worth $37,000 after purchasing an additional 1,029 shares in the last quarter. Covestor Ltd increased its stake in shares of Certara by 14,940.0% in the third quarter. Covestor Ltd now owns 3,760 shares of the company's stock worth $55,000 after purchasing an additional 3,735 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its stake in shares of Certara by 42.9% in the third quarter. Advisors Asset Management Inc. now owns 4,710 shares of the company's stock worth $68,000 after purchasing an additional 1,414 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.
Certara Company Profile
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
